Keita Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.11 M
as on 11-12-2024
- Satisfied Charges ₹ 2.40 Cr
as on 11-12-2024
- Revenue 16.50%
(FY 2022)
- Profit -31.11%
(FY 2022)
- Ebitda 27.62%
(FY 2022)
- Net Worth 25.91%
(FY 2022)
- Total Assets 92.58%
(FY 2022)
About Keita Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.11 M. The company has closed loans amounting to ₹2.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Poonam Gursale and Dinesh Gursale serve as directors at the Company.
- CIN/LLPIN
U33100MH2010PTC210627
- Company No.
210627
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Dec 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Keita Pharma Private Limited offer?
Keita Pharma Private Limited offers a wide range of products and services, including Vials and Ampoules, Glass Vials, Common Disease Medicines, Nasal Drops, Ear Drops.
Who are the key members and board of directors at Keita Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Gursale  | Director | 06-Dec-2010 | Current |
| Poonam Gursale | Director | 10-Aug-2016 | Current |
Financial Performance of Keita Pharma.
Keita Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 16.5% increase. The company also saw a substantial fall in profitability, with a 31.11% decrease in profit. The company's net worth Soared by an impressive increase of 25.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Keita Pharma?
In 2022, Keita Pharma had a promoter holding of 99.90% and a public holding of 0.10%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Aug 2023 | ₹1.51 M | Open |
Axis Bank Limited Creation Date: 04 Apr 2022 | ₹2.60 M | Open |
State Bank Of India Creation Date: 16 Sep 2022 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Keita Pharma?
Unlock and access historical data on people associated with Keita Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Keita Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keita Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
